PHASE II STUDY EVALUATING THE ACTIVITY AND TOXICITY OF A BIWEEKLY SCHEDULE OF GEMCITABINE AND PACLITAXEL IN ANTHRACYCLINE-PRETREATED BREAST CANCER

被引：0
|
作者：
Spinelli, G. P. [1 ]
Di Seri, M. [1 ]
Mezi, S. [1 ]
Oliveti, A. [1 ]
Tomao, F. [1 ]
Petricola, F. [1 ]
Rosati, S. [1 ]
Ricciardi, S. [1 ]
Coletta, D. [1 ]
Romiti, A. [1 ]
Frati, L. [1 ]
Tomao, S. [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [1] Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: A phase II study
    Michelotti, A
    Gennari, A
    Salvadori, B
    Tognoni, A
    Tibaldi, C
    Baldini, E
    Conte, PF
    [J]. ANNALS OF ONCOLOGY, 1996, 7 (08) : 857 - 860
  • [2] Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients -: A phase II study
    Ferraresi, V
    Milella, M
    Vaccaro, A
    D'Ottavio, AM
    Papaldo, P
    Nisticò, C
    Thorel, MF
    Marsella, A
    Carpino, A
    Giannarelli, D
    Terzoli, E
    Cognetti, F
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (02): : 132 - 139
  • [3] Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer
    Batista, N
    Perez-Manga, G
    Constenla, M
    Ruiz, A
    Carabantes, F
    Castellanos, J
    Barón, MG
    Villman, K
    Söderberg, M
    Ahlgren, J
    Casinello, J
    Regueiro, P
    Murias, A
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (09) : 1740 - 1746
  • [4] Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer
    N Batista
    G Perez-Manga
    M Constenla
    A Ruiz
    F Carabantes
    J Castellanos
    M Gonzalez Barón
    K Villman
    M Söderberg
    J Ahlgren
    J Casinello
    P Regueiro
    A Murias
    [J]. British Journal of Cancer, 2004, 90 : 1740 - 1746
  • [5] Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
    Helgason, H. H.
    Kruijtzer, C. M. F.
    Huitema, A. D. R.
    Marcus, S. G.
    Huinink, W. W. ten Bokkel
    Schot, M. E.
    Schornagel, J. H.
    Beijnen, J. H.
    Schellens, J. H. M.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (07) : 794 - 800
  • [6] Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
    H H Helgason
    C M F Kruijtzer
    A D R Huitema
    S G Marcus
    W W ten Bokkel Huinink
    M E Schot
    J H Schornagel
    J H Beijnen
    J H M Schellens
    [J]. British Journal of Cancer, 2006, 95 : 794 - 800
  • [7] Docetaxel toxicity and activity in anthracycline-pretreated metastatic breast cancer (MBC)
    Milella, M
    Vaccaro, A
    Ferraresi, V
    D'Ottavio, AM
    Papaldo, P
    Nisticò, C
    Marsella, A
    Thorel, MF
    Carpino, A
    Cercato, MC
    Terzoli, E
    Cognetti, F
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 : S42 - S42
  • [8] A phase I study -: UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer
    Scholz, U
    Lück, HJ
    Canzler, U
    Robner, D
    Kühnle, H
    [J]. ONCOLOGY-NEW YORK, 2000, 14 (10): : 44 - 46
  • [9] Phase I–II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines
    Patrizia Vici
    Alessandra Fabi
    Giulio Metro
    Domenico Sergi
    Diana Giannarelli
    Luigi Di Lauro
    Gerold Bepler
    Federica Tomao
    Francesco Cognetti
    Francesca Conti
    Massimo Lopez
    [J]. Cancer Chemotherapy and Pharmacology, 2011, 67 : 687 - 693
  • [10] Docetaxel (DT) in anthracycline-pretreated advanced breast cancer (ABC): Toxicity and activity
    Ferraresi, V
    Vaccaro, A
    Milella, M
    D'Ottavio, AM
    Papaldo, P
    Nistico, C
    Thorel, MF
    Marsella, A
    Terzoli, E
    Cognetti, F
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 19 - 19
12345